Skip to main content

Table 1 Clinical and Pathological features of ovarian cancer patients according to pathogenic and likely pathogenic BRCA1 and BRCA2 variants

From: Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil

Characteristics BRCA 1/2 wt
(N = 125)
BRCA 1/2 mut
(N = 33)
p
Median age at diagnosis in years (IQR) 54.44 (42.7–67.7) 60.65 (43.8–67.2) 0.946
Time between diagnosis and genetic testing in months (IQR) 23.91 (10.75–45.15) 18.95 (8.86–39.77) 0.390
Histology    0.109
 Serous 83 (66.4) 27 (81.8)  
 Non-serous 40 (32.0) 6 (18.2)  
 Missing 2 (1.2) 0 (0)  
FIGO stage    0.288
 I/II 29 (23.2) 5 (15.1)  
 III/IV 86 (68.8) 26 (78.8)  
 Missing 10 (8.0) 2 (6.1)  
Personal history of breast cancer    0.001
 Positive 4 (3.2) 8 (24.2)  
 Negative 105 (84.0) 22 (66.6)  
 Missing 16 (12.8) 3 (9.1)  
Family history for breast and/or ovarian cancer    0.115
 Positive (first and/or second degree relatives) 55 (44.0) 20 (60.6)  
 Negative 54 (43.2) 11 (33.3)  
 Not completely Known/ Unknown 16 (12.8) 2 (9.1)  
Median pretreatment CA-125 (IQR) 436.5 (117.5–1163.0) 681.5 (126.5–2062.5) 0.351
Treatment    0.414
 First-line 65 (52.0) 19 (57.7)  
 Platinum-sensitive 41 (32.8) 11 (33.3)  
 Platinum-resistant 13 (10.4) 1 (3.0)  
 Unknown 6 (4.8) 2 (6.0)  
  1. BRCA1/2 wt = no pathogenic or likely pathogenic variants. BRCA1/2 mut = presence of pathogenic or likely pathogenic variant. IQR Interquartile range